Last edition
News about "ProMIS Neurosciences"
ProMIS Neurosciences Reports Positive Interim Phase 1b Results for Alzheimer's Therapy PMN310
ProMIS Neurosciences has reported positive six-month interim data from its Phase 1b PRECISE-AD trial, with PMN310 demonstrating a favourable safety profile, no ARIA-E cases and encouraging biomarker trends in patients with Alzheimer's disease.
ProMIS Neurosciences | 30/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members